Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
A study carried out by Kaposi-Novak has found that a Met-regulated expression signature correlated vascular invasion rate and decreased mean survival time and microvessel density in a subset of human HCC and liver metastases (Kaposi-Novak et al., 2006)
The angiotensin IV analog Nle-Tyr-Leu--(CH 2 -NH 2 ) 3-4 -His-Pro-Phe (Norleual) can act as a hepatocyte growth factor/c-Met inhibitor
Research Use Limitation Used solely for in vitro experiments Not permitted for clinical trials involving humans Not permitted for human or veterinary administration Not permitted for investigational human use Independent third-party laboratory verification by Liquilabs s.r.o
Threonine 11 of research subjects NAD(+)-dependent 15-hydroxyprostaglandin [PMID: 12144871] Laboratory literature summary: Threonine 11 of research subjects NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase may interact with NAD(+) during catalysis
Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
US$ 29.61
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
US$ 27.93
US$ 28.80
:format(webp))
US$ 24.27
US$ 23.86
